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INTRODUCTION 
 Nonthyroid illness syndrome or sick euthyroid syndrome refers to 
alterations that occur in thyroid hormone levels in response to any critical 
illness like sepsis, ARDS, patients on mechanical ventilation and also any 
ICU patients. 
 The metabolic response to any critical illness involves every organ 
but the underlying pathology is not completely understood. Despite the 
primary diagnosis, as a stress induced response in critical illness, a state of 
hypermetabolism prevails leading to increased energy expenditure, 
hyperglycemia and muscle loss. 
 Thyroid hormone alterations commonly occur in critical illness in 
patients with no previous known intrinsic thyroid disease. The changes in 
thyroid hormone levels is not an isolated phenomenon as it is also 
associated with changes in other endocrine axis as a response to stress. 
 Various theories have been proposed for alterations in thyroid 
function. In early course of the illness, the peripheral conversion of T 4 to 
T3 is reduced leading to decreased  free T3 with normal or reduced T4 
associated with an increase in reverseT3( rT3 ) and no alterations in TSH. In 
prolonged illness, central hypothyroidism occurs leading to reduced TSH 
and T4 along with T3. 
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 In this study thyroid profile is taken from patients admitted in ICU on 
day 1 and day 7 and to correlate the levels the thyroid hormones and the 
outcome of the patients and also to know the outcome of the disease can be 
prognosticated with thyroid function tests in patients admitted in ICU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS & OBJECTIVES 
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AIMS AND OBJECTIVES 
1) To study the relation between thyroid hormone level changes and 
critical illness in ICU patients. 
2)  To predict the mortality based on thyroid hormone levels in ICU 
patients. 
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REVIEW OF LITERATURE 
INTRODUCTION 
Thyroid gland present in the neck produces two hormones namely 
triiodothyronine(T3) and thyroxine(T4). These hormones play a vital role in 
cell differentiation during development  and maintains homeostasis 
including metabolic and thermogenic in adults. 
ANATOMY 
Thyroid gland(Greek thyreos, shield, and eidos, form)[1] is one of the 
most vascular organ weighs around 10 - 20 grams in adults.[2] Thyroid 
volume in men is greater than women which is measured by 
ultrasonography(USG). 
It is a butterfly shaped organ present in middle of the neck. Thyroid 
gland extends just below cricoid cartilage and encircles trachea 
anterolaterally and extends just above suprasternal notch. 
It consists of two lobes laterally and an isthmus which connects the 
two lobes. Isthmus is 0.5cm thick , 2cm high and 2cm wide. Each lobe is 
around 4cm in height and 2 – 2.5cm thick[3] and have a superior and inferior 
lobe. Pyramidal lobe, a finger like projection extends from isthmus just  left 
to the midline. It is usually directed in an upward direction. 
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Figure 1 – Anatomy of thyroid gland 
EMBRYOLOGY 
Thyroid gland develops around 3rd week of intra uterine life. It is 
mainly derived from endoderm. The fourth pharyngeal pouch from its 
ventral portion develops into thyroid lobes. 
Pyramidal lobe develops from thyroglossal duct as it descends and 
attaches itself to isthmus. 
Ultimobranchial bodies, the neural crest cells arises from fourth and 
fifth brachial arches give rise to parafollicular C cells which synthesize 
calcitonin. 
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BLOOD SUPPLY 
Thyroid is highly vascular and it has superior and inferior thyroid 
arteries which are present on both sides. 
1) Superior thyroid artery- first branch of external carotid artery.  
2) Inferior thyroid artery- arises from thyrocervical trunk which again is 
a branch of subclavian artery. 
3) Thyroidea ima artery- in 3% population, branch of aortic arch.[4]  
The average estimated blood flow to thyroid gland is around 4 – 
6ml/min/gram of thyroid tissue. 
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Figure 3 – Histology of thyroid gland 
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THYROID HORMONE SYNTHESIS AND SECRETION 
Thyroid gland secretes T4 and T3. T4 levels predominate in secretion 
whereas T3 is more potent than T4. T4 gets converted to T3 in the 
peripheral tissues by deiodination. 
Iodine forms the primary component in thyroid hormones. Dietary 
iodine gets absorbed from intestine and enters circulation. Minimum dietary 
intake required for maintain normal thyroid function is 150μg/day in adults. 
Normal uptake of iodine by thyroid gland is around 120μg/day in which 
around 80μg/day is secreted as thyroid hormone and remaining enters into 
circulation. 
Iodine enters into thyrocytes through sodium/iodine symporter(NIS) 
present in the basolateral membrane of thyrocytes. This channel transports 
two sodium and one iodine ion into the cell.[6] This is a secondary active 
transport. NIS expression in the cell is mediated by thyroid stimulating 
hormone. 
Iodine leaves the cell across the apical membrane to enter the colloid 
where thyroid hormone synthesis occurs, it leaves the cell via 
chloride/iodine exchanger (pendrin). 
Iodine then undergoes organification at colloid thyrocyte interface. 
First it gets oxidized to form iodine and then gets incorporated into 
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thyroglobulin. Thyroglobulin in a glycoprotein  synthesized by thyrocytes 
and leaves the cells to enter colloid by exocytosis. Thyroperoxidase which is 
present in apical membrane of thyrocytes mediates the oxidation and 
incorporation of iodine into thyroglobulin.[7] 
Thyroid hormone synthesis involves a multistep process. First 
product formed is monoiodotyrosine (MIT) which is nothing ut 
thyroglobulin and oxidized iodine. Another molecule of iodine gets 
incorporated to form diiodotyrosine (DIT). Two molecules of DIT combine 
to form T4 by oxidation condensation reaction. T3 is formed when 
monoiodotyrosine condense with diiodotyrosine. When it occurs in a 
reverse manner (DIT + MIT) reverse T3 is synthesized.[8] 
The daily secretion by thyroid gland consists of around 80 μg of T4, 4 
μg of triiodothyronine and 2 μg of reverse T3 whereas DIT and MIT are not 
secreted. They are deiodinated by iodotyrosinase deiodinase  which is 
present in microsomes. They recycle iodine which is utilized in the next 
cycle of thyroid hormone synthesis. T3 and T4 are resistant to deiodination 
by this enzyme and they appear in circulation. 
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Figure 4 – Synthesis and secretion of thyroid hormone 
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THYROID HORMONE TRANSPORT  
 Thyroid hormones are present in circulation in free and protein bound 
form. T3 and T4 are lipophilic. Free and protein bound hormones are in 
equilibrium with one another. Free form is secreted by the gland. Free form 
is the active one and it mediates the action and feedback inhibition to 
pituitary gland and inhibiting the secretion of TSH. 
 The importance of protein binding is that the protein bound form 
maintains the large pool of hormones which are utilized readily when 
needed.[9] 
 Thyroid hormones are bound to three proteins namely albumin, 
transthyretin (prealbumin) and thyroxine binding globulin(TBG).[10] Of 
these albumin has the largest capacity and TBG has the least capacity to 
bind to the hormones. However in regard to the affinity of binding most of 
the hormones are bound to TBG. The half life of albumin is 13 days, TBG is 
around 5 days and that of transthyretin is 3 days. 
 T4 is more bound to T3 in plasma. This explains the longer half life 
of T4 when compared to T3. The half life of T4 is around 6-7 days. Since 
T3 is less protein bound it has faster onset of action than T4 at the level of 
tissues. 
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Figure 5 – Transport of thyroid hormones 
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METABOLISM OF THYROID HORMONE 
 Thyroid hormones are deiodinated principally in the liver, kidney and 
many other tissues. The importance of deiodination is that in addition to 
catabolism of the hormones it also helps in peripheral synthesis of T3 is the 
primary mediator of thyroid hormone actions at the level of tissues.  
Only around 13% of circulating T3 is secreted by thyroid whereas the 
remaining 87% are synthesized by peripheral deiodination. Cerebral cortex 
and pituitary have high T3/T4 ratio due to the expression of deiodinases.[11] 
 There are three deiodinases present in the body D1, D2, and D3. D1 is 
seen in liver, pituitary, thyroid and kidneys. It mainly involves in the 
peripheral conversion of T4 to T3.[12] D2 is seen in brain, brown fat and 
pituitary. In brain it is present in astroglia and responsible for supply of T3 
in brain.  
D3 is presnt in reproductive tissues and brain and mainy involves in 
the synthesis of RT3. They are conjugated to sulfates and glucoronides in 
liver and secreted through bile and some enter enterohepatic circulation and 
rest are excreted in stools. 
REGULATION OF THYROID SECRETION 
 Thyroid function is regulated by TSH secreted from anterior pituitary 
gland. TSH secretion is regulated by TRH secreted from hypothalamus. The 
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negative feedback inhibition for TSH secretion is mediated by T4 and T3. 
TSH is also inhibited  during periods of stress. 
 TSH is a glycoprotein containing 211 aminoacids having two 
subunits α and β and they are encoded in chromosome 6 and 1 respectively. 
Both subunits are noncovalently linked with each other. TSH α is similar to 
FSH, LH, hCG α. β subunit mediates the function of TSH.  
The half life of TSH is around 60 min. TSH is metabolized mainly in 
kidneys and to some extent in the liver. TSH secretion is diurnally variable. 
The secretion peaks at midnight and declines during the day. Since α 
subunit of hCG is similar to TSH it can activate thyroid receptors in large 
concentrations.  
TSH receptors are G protein coupled receptors which acts via 
phospholipase C. T3 and T4 inhibit the secretion of TSH and TRH.[13] 
OTHERS FACTORS AFFECTING THYROID GROWTH 
 Thyroid gland expresses IGF-1, EGF promote growth of the gland 
whereas INF γ and TNF inhibit the growth. 
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Figure 6 – Regulation of thyroid hormones 
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 MECHANISM OF ACTION OF THYROID HORMONES 
 Thyroid hormones enter the cells and bind to thyroid receptors in the 
nuclei which then with the help of zinc fingers bind to DNA and mediates 
the function by expressing various genes which codes for protein and 
mediates various functions. 
 T3 is around five times more potent than T4. RT3 does not mediate 
any functions. 
 
Figure 7 – Metabolism of thyroid hormones 
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PHYSIOLOGICAL EFFECTS OF THYROID HORMONES 
Table 1 – Functions of thyroid hormones 
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LABORATORY MEASUREMENT OF THYROID FUNCTION 
 We use the following tests to assess thyroid function. 
1. Thyroid stimulating hormone(TSH) 
2. Serum total T4 
3. Serum total T3 
4. Serum free T3/ T4  
Serum TSH measurement: Normal TSH levels range from 0.4-
5mU/L. Second generation TSH immunometric assays can measure even 
upto 0.1mU/L.[14]  TSH measurement is primarily useful in differentiating 
between hyperthyroidism from hypothyroidism and euthyroidism. But these 
assays cannot assess the degree of hyperthyroidism. Third generation assays 
can measure values <0.1mU/L and can be useful to assess the degree of 
hyperthyroidism. 
 TSH levels can also be used to initiate treatment in hypothyroidism. It 
also can used to follow up the patients and dosage adjustment. 
 Age related changes can occur with TSH values, it was illustrated in 
the National Health and Nutrition Examination Survey III (NHANES III). 
As per this survey, TSH concentrations were higher in older patients. For 
example around 70% of subjects have value around 4.5mU/L within the 
normal range. 
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Serum T3 and T4: They can be measured by chemiluminometric 
assay, radioimmunoassay or other   immunometric assays. They measure 
both subgroups of hormones which are protein bound and free form. Normal 
total T4 values range from 4.6 to 11.2 mcg/dL. Total T3 values range from 
75 to 195 ng/dL. 
 Serum free T3 and T4: Since  bound hormone represents only the 
circulating pool and not the hormone which is readily available for cellular 
uptake and for nuclear receptor interaction assays to measure the free 
hormone levels are developed. During period of illnesses and intake of 
certain drugs can ater the protein binding of T3 and T4. This produces a 
disarray between free and total T3 and T4 levels. Free T4 can be measured 
by direct measurement, equilibrium dialysis, free hormone levels using 
thyroxine binding index and T3 resin uptake. 
CLINICAL USES OF THYROID FUNCTION TESTS 
1) Screening for thyroid dysfunction        
Serum TSH measurement is the initial step in screening process. If 
TSH levels are elevated patients are screened for hyperthyroidism with 
serum free T3  are suband T4. If TSH leves are low patients are screened for 
hypothyroidism.                
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2) Monitoring drug levels during treatment  
Patients with hypothyroidism who are taking levothyroxine, the 
adequacy of dosage can be monitored with serum TSH measurement. If 
TSH levels are elevated, L-thyroxine dosage has to increased.[15] If the 
levels are low dosage has to be lowered. Serum TSH is not a sensitive index 
in monitoring hypothyroidism. 
Serum TSH can ony detect hyperthyroidism and not the degree of 
hyperthyroidism. Serum T3 levels are much more elevated the serum T4 in 
many patients. So serum T3 levels can be utilized to monitor patients with 
hyperthyroidism on treatment. 
ANTITHYROID ANTIBODY 
 Antibodies directed against certain thyroid antigens can be measured 
in certain autoimmune conditions which may cause hypothyroidism or 
hyperthyroidism. 
 Antibody against thyroglobulin(Tg) – thyroglobulin is synthesized in 
follicular cells and secreted and stored as colloid. 
 Antibody against thyroperoxidase(TPO) – TPO is an enzyme that 
catalyzes the iodination of Tg and production of MIT and DIT.[16] 
 Almost all patients with hashimoto’s thyroiditis have elevated 
antibodies against Tg and TPO. 
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 Antibodies against TSH receptor can either stimulating, blocking or 
neutral. Stimulating antibodies are seen in grave’s disease and blocking 
antibodies are seen in hashimoto’s thyroiditis.[16] 
HYPOTHYROIDISM 
 Hypothyroidism is commonly diagnosed in females           ( female : 
male ratio = 5-8 : 1 ). Prevalence of hypothyroidism in community based 
surveys is around 0.1 to 2 percent. The prevalence of subclinical 
hypothyroidism in adults is 4 – 10 percent. 
 Hypothyroidism can be : 
1) Primary – intrinsic thyroid abnormality, pituitary and 
hypothalamic function are normal 
2)  Secondary -  hypothyroidism due to pituitary problem leading to 
decreased TSH secretion  
3)  Tertiary – hypothyroidism due to hypothalamic disorder with 
insufficient TRH stimulation to pituitary gland. 
SUBCLINICAL HYPOTHYROIDISM 
 This is an entity that can be described biochemically. Patients may be 
asymptomatic or can have only vague symptoms. Classically these patients 
have normal T4 and T3 concentrations with elevated TSH levels.[17] 
 
23 
 
CAUSES OF HYPOTHYROIDISM 
Table 2 – Causes of hypothyroidism 
 
 
 Figure 8 – Signs an
24 
d symptoms of hypothyroidism 
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LABORATARY VALUES IN HYPOTHYROIDISM 
Table 3 – Lab values in hypothyroidism 
 
MANAGEMENT – AN OVERVIEW 
              
Figure 9 – Management algorithm for hypothyroidism 
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HYPERTHYROIDISM 
 Hyperthyroidism is a disease with constellation of symptoms due to 
excessive production of thyroid hormones by thyroid gland ( hyperthreosis 
). Thyrotoxicosis is due to presence of increased thyroid hormones of any 
cause, one of which is hyperthyroidism. 
CAUSES OF HYPERTHYROIDISM 
Table 4 – Causes of hyperthyroidism 
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Figure 10 – Signs and symptoms of hyperthyroidism 
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INVESTIGATION
 
Figure 11 – Approach to hyperthyroidism 
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OVERVIEW OF MANAGEMENT 
     
 
Figure 12 – Management overview for hyperthyroidism 
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THYROID FUNCTION IN CRITICAL ILLNESS 
 This entity in relation to thyroid function is also known as sick 
euthyroid syndrome, low T3 syndrome or nonthyroid illness syndrome. In 
any crictical illness, there is increased usage of energy, a hypercatabolic 
state leading to muscle loss.[18] In these states there are alterations in thyroid 
hormone levels in a previous euthyroxinemic leading to sick euthyroid 
syndrome. Alterations in thyroid function is a common phenomenon. But 
these changes are never an isolated phenomenon and associated with 
changes in other endocinological abnormalities.  
 Other endocrine changes include increased levels of 
adrenocorticotrophic hormone(ACTH) and serum cortisol levels. Decreased 
levels of gonadotrophin and sex hormone levels are also seen. So sick 
euthyroid syndrome should not be viewed as an isolated phenomenon but as 
a constellation of endocrine abnormalities seen in any critical illness.[19] 
 In order to understand and interpret the thyroid function tests one 
should know the normal physiological changes occurring in hypothalamic-
pituitary-thyroid axis and thyroid hormone metabolism and effects of drugs 
on thyroid hormone metabolism. 
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T3 IN CRITICAL ILLNESS 
 The physiologically active component of thyroid hormones is T3. T3 
levels are reduced in critical illness implies changes in thyroid hormone 
homeostasis and metabolism. Majority of T3 around 80% - 90% are being 
produced from peripheral monodeiodination of T4. This reaction is 
mediated by 5’- monodeiodinase, an enzyme present in liver, kidneys and 
aso other organs. The remaining 10% - 20% are being secreted by thyroid 
gland itself. 
 So inhibition of the enzyme 5’-deiodinase hampers the peripheral 
conversion of T4 to T3. Also many drugs used in ICU like amiodarone, 
corticosteroids and iodine inhibits the peripheral conversion.[20] 
 Majority of patients in ICU have low levels of T3. Liver biopsies 
taken within minutes after death in patients admitted in ICU showed that 
there is decreased concentration and activity of 5’- deiodinase. It also 
demonstrated that the activity of enzyme 5’- monodeiodinase. This enzyme 
is involved in synthesizing reverseT3(rT3). Also some patients with fatal 
illness reduced tissue levels of T4 and T3. 
 A number of mechanisms have been proposed that are involved in 
decreased activity of 5’- deiodinase. The reasons may be due to any one of 
the following: 
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1) Treatment with glucocorticoids 
2) Cytokines (tumor necrosis factor alpha, interferon alpha, 
interleukin-6 and NF-kB) released in periods of stress.[21] 
3) Non – esterified fatty acids which are circulating inhibitiors of 
deioinase activity. 
4) Administration of drugs that inhibit the peripheral conversion of 
T4 to T3 like propronalol and amiodarone. 
REVERSE TRIIODOTHYRONINE( rT3 ) 
 The rise in rT3 values along with the fall in T3 hormone levels are 
one of the most common findings observed in patients with critical illness. 
 The pathway involves the synthesis of rT3 catalyzed by 5’- 
deiodinase is called inactivating pathway. Since the activity of 5’- 
monodeiodinase activity is also reduced in critical  illness, the conversion of 
rT3 to diiodothyronine is reduced. This pathway also contributes to 
increased levels of rT3 levels in patients with critical illnesses. 
THYROXINE ( T4 ) 
 Within 1 to 2 days of critical illness serum T4 levels can be reduced. 
Many mechanisms have been proposed which include reduced levels of 
thyroxine binding proteins like albumin, thyroid binding prealbumin and 
thyroid hormone binding globulin(TBG). Drugs like carbamazepine, aspirin, 
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phenytoin preferentially binds to the binding proteins. These drugs thus 
compete with thyroid hormones in protein binding which results in 
increased levels of free T4 and low levels of total T4. This phenomenon is a 
transient.[22] 
 Other factors include the presence of circulating inhibitors which 
prevents T4 protein binding like fatty acids, abnormal iodine uptake and 
abnormal peripheral metabolism. Drugs like barbiturates accelerate the 
clearance of T4 resulting low levels. 
FREE T4 
 Though total T4 levels are low, free T4 levels remain normal in 
critical illness unless the illness is severe and prolonged.  
In prolonged critical illnesses there is suppression of hypothalamic – 
pituitary axis. This leads to decreased TSH levels and T4 synthesis is 
reduced. This decrease in free T4 indicates the severity and it can be used as 
a predictor of poor outcome. 
THYROTROPHIN( TSH ) 
 Normally TSH secretion is stable and controlled by thyroid 
hormones, neuropeptides and neurotransmitters. Under normal conditions, 
thyrotrophin stimulating hormone (TSH) is the main stimulating factor. The 
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effect of TSH is enhanced by catecholamines. The main inhibitors include 
dopamine and somatostatin.  
In sick euthyroid syndrome, TSH levels are usually normal. It may be 
low in prolonged illnesses. Serum TSH assays can detect around 0.01mU/L. 
During recovery period from critical illness there may be transient 
rise in TSH levels upto 20mU/L. Few of these patients with elevated TSH 
levels when evaluated later once they recovered from the illness found to 
have hypothyroidism. 
As seen earlier, the initial changes in thyroid hormone homeostasis is 
due to peripheral changes such as impaired deiodination and decreased 
release of thyroid hormones from the gland. Later on it is due to centrally 
induced hypothyroidism. Postmortem examination in these patients showed 
that there is decreased follicular size in thyroid gland, decreased expression 
of TRH mRNA in paraventricular nucleus of hypothalamus.[23] 
 Clinically, low T3 and T4 in association with normal, near normal or 
low TSH suggests the development of central hypothyroidism. These 
alterations may be a self protective mechanism so that energy can be 
preserved. These alterations are usually transient and normalizes once the 
patient starts to recover. During this period initially TSH rise followed by 
normalization of T4 levels. The half life of TSH is in hours while that of T4 
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is in days. So T4 values lag behind TSH levels. If TFT done during this 
period and interpreted the values may simulate primary hypothyroidism. 
ASSESSMENT OF THYROID FUNCTION IN ICU 
 The reduced activity of 5’- monodeiodinase is not recognized since 
measurement of serum T3 is not the initial step in thyroid function tests. So, 
in patients with low TSH levels measurement of serum T3 levels help to 
differentiate between hyperthyroidism and sick euthyroid syndrome. In 
earlier T3 levels are elevated where as in the later the levels are decreased. 
 In an ICU patient, the differential diagnosis for low T4 and T3 should 
also include hypothyroidism. Here the measurement of rT3 helps in 
differentiating nonthyroid illness and secondary hypothyroidism. In 
hypothyroidism rT3 levels are low. In sick euthyroid syndrome, rT3 levels 
are elevated. 
 To conclude in assessing thyroid function in ICU two things to 
remember include: 
1)  Unless there is a strong suspicion of thyroid  dysfunction, thyroid 
function should not be assessed. 
2) If there is a strong suspicion, TSH alone is not sufficient to say 
that patient is having thyroid dysfunction.[24] 
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THYROID HORMONE REPLACEMENT IN NONTHYROID 
ILLNESS 
 It is still a matter of debate whether the changes that occur during 
critical illness are due to a protective mechanism or a maladaptive 
mechanism during periods of stress.  
 If the changes are due to pathologic process treatment with thyroxine 
will improve the outcome. If it is due to an adaptive process then treatment 
may worsen the outcome. The presence of low T3 and T4 in patients with 
critical illness have worse prognosis. 
 Only few studies have been conducted regarding treatment with 
supplemental thyroxine in non thyroidal illness patients. Brent and 
Hershman conducted one of those studies involving the effect of thyroxine 
replacement in patients admitted in intensive care units. 
 Inclusion criteria for this study was patients with serum T4 levels of 
<5 µg/dL with previous normal thyroid function. Patients were administered 
levothyroxine or placebo intravenously. 
 The observed result was there no significant difference in mortality 
between study population and controls. In fact T4 supplementation was 
found to be harmful as it hindered the normalization of thyroid axis during 
recovery phase. 
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 Since the peripheral conversion of T4 to T3 is significantly 
suppressed in critical illness, one can say that levothyroxine 
supplementation does not appear to be beneficial.[25] 
 Another factor to be noted is that hepatic deiodinase is a 
selenoprotein. Selenium deficiency commonly occurs in critical illness 
particularly in sepsis. Thus selenium supplementation may result in early 
normalization of T4 and rT3. 
 Becker et al done a study in burn patients by replacing 
liothyronine(T3). They also concluded that there is no benefit in mortality. 
The most reasonable option is not to treat sick euthyroid patients. 
 Thyroid function tests can be useful in predicting the outcome of the 
patients. Among all the parameters free T3 has more sensitivity in 
predicting the outcome when compared with T4 and TSH. the levels of rT3 
found to elevated in sick euthyroid syndrome. 
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DRUGS CAUSING ALTERATIONS IN THYROID FUNCTION 
1)HYPOTHYROIDISM 
Table 5 – Drugs casing hypothyroidism and its mechanism 
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2. DRUGS CAUSING HYPERTHYROIDISM 
Table 6 – Drugs causing hyperthyroidism and its mechanisms 
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DRUGS CAUSING ABNORMAL THYROID FUNCTION TESTS 
WITHOUT THYROID DYSFUNCTION 
Table 7 – Drugs causing thyroid dysfunction 
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SCORING SYSTEMS USED TO PREDICT ICU MORTALITY 
 The care for critically ill patients in ICU has advanced over past 
decades. The clinical knowledge of the care provider along with illness 
scoring systems, the outcome of patients can be predicted. 
 Scoring systems for ICU patients can be classified into scoring 
systems that are specific for organ system/ specific disease (eg.Glasgow 
coma scale) and non specific (generic) scoring systems that can be used for 
all patients irrespective of the diagnosis. 
PURPOSES OF SCORING SYSTEMS 
 Five major uses of scoring systems include : 
1) It can be useful in randomized control trials and investigations. 
2) Quantifies the severity of illness and for resource allocation. 
3) To compare the quality of care provided in different ICUs and in 
same ICU over a period of time. 
4) To assess the prognosis of patients in ICU and helping family 
members in making decisions regarding ICU care. 
5) To assess whether the patients are suitable for specific novel 
treatment. ( APACHE II is used for prescribing drotregocin alpha ) 
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TYPES OF ICU SCORING SYSYEMS 
Figure 13 – Classification of ICU scoring systems 
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SPECIFIC MODELS 
First generation -  APACHE I 
Second generation – APACHE II, SAPS I, MPM I 
Third generation – APACHE III, SAPS II, MPM II 
Fourth generation – APACHE IV, SAPS III, MPM III 
ACUTE PHYSIOLOGICAL AND CHRONIC HEALTH 
EVALUATION SCORE (APACHE) II 
In 1981, APACHE scoring system was initially developed to assess 
the severity in ICU patients. In 1985 William Knaus et al who were the 
aurthors of initial scoring system published APACHE II.[26] The advantage 
of APACHE II was that it can predict the mortality in ICU patients. It is still 
the most commonly used scoring systems to predict the outcome.   
 The scores range from 0 to 71 points. Physiological variables 
contribute around 60 points. Around 6 points for age and 5 points for 
previous health status. 
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Table 8 - APACHE II Score 
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APACHE III 
 This scoring system was developed in 1988-1989 
 APACHE III included acute physiological score (APS), age and 
chronic health status. It has scores from 0 to 299. 252 points for 
physiological variables, 24 for age and 23 for chronic health status. 
 The major limitation of this scoring system is the calculating software 
is very expensive one which makes it difficult to use APACHE III in all 
centres. 
APACHE IV 
  It was devised in 2006. It is more complex as it has 142 variables. It 
is done and validated only in ICUs in USA. 
SIMPLIFIED ACUTE PHYSIOLOGICAL SCORE(SAPS) 
 SAPS system of scoring came into practice in 1984. It used 13 
variables and age in the scoring system. Like APACHE, SAPS scoring also 
done within 24 hours to predict the mortality. 
SAPS II 
 Jean roger Le gall et al devised SAPS II in 1993. This score. SAPS II 
included 17 variables. The maximum score is 163 and the minimum is 0. It 
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is calculated within 24 hours of admission. The exclusion criteria included 
age <18 years, myocardial infarction, burns and cardiac surgery. 
Table 9 – SAPS II Score 
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MORTALITY PREDICTION MODEL II 
 Mortality prediction model was devised in 1993. Researchers utilized 
the same variables and exclusion criteria used in SAPS II. This scoring 
system is calculated at the time of admission ( MPM II0 ) and 24 hours after 
admission ( MPM II24 ) for periction of mortality. 
SEQUENTIAL ORGAN FAILURE ASSESSMENT(SOFA) 
 SOFA was initially developed in 1994 to describe organ dysfunction 
in patients with sepsis. Nowadays, it has since been validated to describe the 
degree of organ dysfunction in various ICU patient groups with organ 
dysfunctions not due to sepsis.[27] 
The SOFA score involves six organ systems (respiratory, 
cardiovascular, renal, hepatic, central nervous, coagulation), and the 
function of each is scored from 0 (normal function) to 4 (most abnormal), 
giving a possible score of 0 to 24.Mortality rate increases as number of 
organs with dysfunction increases. 
 
 
 
 
49 
 
Table 10 – SOFA Scoring system 
 
 
 
  
50 
 
ICU STAY, THYROID PROFILE AND ICU SCORING SYSTEMS: 
 As discussed earlier, thyroid hormone assessment can be useful in 
predicting the mortality in ICU patients independently. The correlation of 
thyroid hormone assessment and ICU severity scores parallel with each 
other in predicting the mortality. Among the thyroid profile parameters free 
T3 has more sensitivity in predicting the outcome than T4 and TSH because 
T3 is the first hormone to be affected in sick euthyroid syndrome, since the 
main pathogenesis is the reduced peripheral conversion of T4 to T3. 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS  
&  
METHODS 
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MATERIALS AND METHODS 
Study centre:  Intensive care unit(ICU), Institute of internal 
medicine, Rajiv Gandhi government general 
hospital, Chennai-3 
Study design:   Prospective study 
Sample size:   40 patients 
Duration of study:   6 months 
Inclusion criteria:  
1. Patients admitted in ICU irrespective of the 
diagnosis. 
 
2. Patients with ICU stay more than 7 days. 
 
Exclusion criteria: 
1. Patients with previous intrinsic thyroid, hypothalamic 
– pituitary axis disease. 
 
 
2.  Usage of iodine contrast agents in the past 8 weeks. 
 
3. Usage of drugs causing hypothyroidism. 
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METHODOLOGY 
Data collection and methods: 
 Patients eligible for the study are subjected to clinical 
examinations and investigations. 
Methodology:  
 Patients admitted in ICU irrespective of their primary 
diagnosis are selected for this clinical study as per 
inclusion/exclusion criteria and are subjected to history taking and 
clinical examination after obtaining informed consent.  
After clinical examination patients will be subjected for 
routine investigations like complete hemogram, renal function 
tests, liver function tests, arterial blood gas analysis, blood and 
urine culture and sensitivity( if needed). They are also subjected to 
thyroid function test on day 1 of their ICU stay. 
All the patients in the study are followed up in ICU as they 
are getting treated and their status is monitored over a week. After 
1 week time patients are again subjected to thyroid function tests 
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on day 7 of their ICU stay. Clinical progression over days is 
observed in terms of recovery from the illness or death of the 
patient. Finally thyroid function tests are analyzed whether they 
can predict the outcome of the patient by serial monitoring over 7 
days. 
 
Investigation details: 
 Serum thyroid profile 
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Ventilator requirement 
Table 13 – patients requiring ventilator 
ventilator Frequency Percent 
Yes 20 50.0 
No 20 50.0 
Total 40 100.0 
 
 In our study, out of 40 patients 20 of them were on ventilator. 
Figure 16 – Ventilator requirement 
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Age in Years and Outcome 
Table 17 – Age in years and outcome 
Age in 
years 
  
  
Outcome Total 
  
P value 
Alive Died 
Below 
30 
  
  
Count 5 4 9  
 
 
 
 
 
 
 
 
 
 
 
 
0.080 
% within 
Age in years 55.6% 44.4% 100.0% 
% within 
Outcome 20.8% 25.0% 22.5% 
31-40 
  
  
Count 9 1 10 
% within 
Age in years 90.0% 10.0% 100.0% 
% within 
Outcome 37.5% 6.3% 25.0% 
41-50 
  
  
Count 8 6 14 
% within 
Age in years 57.1% 42.9% 100.0% 
% within 
Outcome 33.3% 37.5% 35.0% 
Above 
50 
  
  
Count 2 5 7 
% within 
Age in years 28.6% 71.4% 100.0% 
% within 
Outcome 8.3% 31.3% 17.5% 
 Total Count 24 16 40 
% within 
Age in years 60.0% 40.0% 100.0% 
% within 
Outcome 100.0% 100.0% 100.0% 
 
In our study, even though 14 out of 40 patients were in the age group 
between 41- 50, this is not statistically significant. The p value of this 
correlation is 0.080 which is not statistically significant. 
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Sex and Outcome 
Table 18 – Sex and outcome 
Sex 
  Outcome Total 
P value 
  Alive Died   
Male 
  
  
Count 
13 10 23 
 
 
 
 
 
 
      .601 
% within Sex 
56.5% 43.5% 100.0% 
% within Outcome
54.2% 62.5% 57.5% 
Female 
  
  
Count 
11 6 17 
% within Sex 
64.7% 35.3% 100.0% 
% within Outcome
45.8% 37.5% 42.5% 
Total Count 
24 16 40 
% within Sex 
60.0% 40.0% 100.0% 
% within Outcome
100.0% 100.0% 100.0% 
 
 In our study, even though 23 out of 40 patients were males and 17 
were females, this difference was not statistically significant. The p value is 
0.601 which is not significant. 
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Comparison Between Ventilator Requirement and Outcome 
Table 19 – Comparison with ventilator requirement and outcome 
VENTILATOR Frequency
 
outcome total P value 
Alive  Dead 
  yes Count  8 12 20  
 
 
0.010 
% within 
outcome 
33.3% 75% 50% 
 
No  
Count  16 4 20 
% within 
outcome 
66.7% 25% 50% 
Total   100% 100% 100% 
 
 In our study, 20 out of 40 patients required ventilator support. This 
value is statistically significant. The p value is 0.010.  
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Comparison Between Comorbid Factor (Diabetes Mellitus) and 
Outcome 
Table 20 – Comparison between diabetes mellitus and outcome 
Diabetes 
mellitus 
Frequency 
 
outcome total P value 
Alive  Dead  
  yes Count  14 8 22  
 
 
0.604 
% within 
outcome 
58.3 50 55 
 
No  
Count  10 8 18 
% within 
outcome 
41.7 50 45 
Total   100 100 100 
 
 
In our study, 22 patients were having diabetes mellitus and 18 were 
not having diabetes mellitus. This difference is not statistically significant 
and the p value is 0.604. 
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Comparison Between Comorbid Factor (Hypertension) and Outcome 
Table 21 – Comparison between hypertension and outcome 
Hypertension  Frequency 
 
outcome total P value 
Alive  Dead  
  yes Count  11 9 20  
 
 
0.519 
% within 
outcome 
45.8 56.3 50 
 
No  
Count  13 7 20 
% within 
outcome 
54.2 43.8 50 
Total   100 100 100 
 
In our study 20 patients were having hypertension and others were 
not having hypertension. This difference is not statistically significant. The 
p value is 0.519. 
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Significance of T3 levels on day 1 and day 7 in Predicting the Outcome 
of Patients. 
Table 23 – Significance of T3 levels in predicting the outcome 
 Outcome N Mean P value 
T3 - 
Day 1 
  
Alive 24 48.13 
0.087 Died 16 42.44 
T3 - 
Day 7 
  
Alive 24 67.33 
0.001** Died 16 33.88 
             
          In our study, Thyroid function tests were done on day 1 of ICU stay. 
The p value for T3 levels on day 1 is 0.087 and for day 7 is <0.001**. Based 
upon the results, the serial measurement of T3 levels will help in predicting 
the outcome of the patients as an independent factor or in association with 
APACHE II scores.  
 
 
 
 
 
72 
 
Significance of T4 levels on day 1 and day 7 in Predicting the Outcome 
of Patients. 
Table  24– Significance of T4 levels in predicting the outcome 
 Outcome N Mean P value 
T4 - Day 1 Alive 24 3.9958 
0.980   Died 16 4.0000 
T4 - Day 7 Alive 24 4.9667 
0.001**   Died 16 3.7000 
 
            In our study, Thyroid function tests were done on day 1 of ICU stay. 
The p value for T4 levels on day 1 is 0.980 and for day 7 is <0.001**. Based 
upon the results, the serial measurement of T4 levels will help in predicting 
the outcome of the patients as an independent factor or in association with 
APACHE II scores. 
         But the p value of T3 levels on day 1 is 0.087 whereas that of T4 is 
0.980. So, when compared to T4, T3 levels will more accurately predict the 
outcome than T4. 
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Significance of TSH levels on day 1 and day 7 in Predicting the 
Outcome of Patients. 
Table 25 – Significance of TSH levels in predicting the outcome 
 Outcome N Mean P value 
TSH - Day 
1 
  
Alive 24 .7754 
0.085 Died 16         .4831 
TSH - Day 
7 
  
Alive 24 1.2988 
0.001** Died 16 0.3462 
 
                 In our study, Thyroid function tests were done on day 1 of ICU 
stay. The p value for TSH levels on day 1 is 0.085 and for day 7 is 
<0.001**. Based upon the results, the serial measurement of TSH levels will 
help in predicting the outcome of the patients as an independent factor or in 
association with APACHE II scores. 
                 The significance increases depending on duration of illness. 
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Correlation Between APACHE II And Thyroid Function Tests On Day 
1 In Predicting The Outcome 
Table 26 – Correlation between APACHE II and TFT on day 1 
   Apache II 
 T3 - Day 1 P value .002 
  N 40 
 T4 - Day 1 P value .551 
  N 40 
 TSH - Day 1 P value .216 
  N 40 
 
 In our study, APACHE II score which is calculated within 24 hours 
of ICU admission is compared with thyroid function tests which is taken on 
day1. The results obtained with this comparison is that on day 1 levels of T3 
significantly correlated with APACHE II scores whereas T4 and TSH levels 
are not statistically significant. 
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Correlation Between APACHE II And Thyroid Function Tests On Day 
7 In Predicting The Outcome 
Table 27 – Correlation between APACHE II and TFT on day 7 
   Apache II 
 T3 - Day 7 P value .001** 
  N 40 
 T4 - Day 7 P value .010 
  N 40 
 TSH - Day 7 P value .013 
  N 40 
 
 In our study, APACHE II score is also compared with thyroid 
function test which is taken on day 7. The results obtained with this 
comparison is that on day 7 levels of T3, T4 and TSH significantly 
correlated with APACHE II scores in predicting the outcome of the patients. 
The significance of T3 is higher when compared to T4 and TSH. 
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DISCUSSION 
 This study was conducted in the patients admitted in ICU irrespective 
of the diagnosis. The study group size was 40. Patients included in the study 
were closely monitored and thyroid function tests were taken on day 1 and 
day 7 as explained in methodology. All the patients are followed till the 
outcome which was either recovery and discharge or death of the patient. 
Outcome analysis was done in comparison with whether thyroid function 
tests were able to predict the outcome of the patients independently. The 
significance is also assessed by comparison of thyroid hormone levels with 
APACHE II scores. Following were the main observations of the study. 
AGE AND SEX DISTRIBUTION: 
 Out of 40 patients, maximum number of patients were observed in the 
age group of 41 – 50 years with the percentage of 35% as observed in the 
frequency distribution table. Out of 40 patients, 23 (57.5%) patients were 
male and 17 (42.5%) patients were female. 
 Chi square tests were applied to these values to observe whether age 
and sex distribution affects the outcome of the study. The observed p values 
for age distribution are 0.080 and for sex distribution is 0.601. Both the 
values are not statistically significant. So age and sex distribution did not 
affect the outcome of the study.   
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COMORBID FACTORS: 
 Out of 40 patients, 22 patients were having diabetes mellitus and 18 
were not having diabetes mellitus. 20 patients were having hypertension and 
20 patients were without hypertension. Statistical tests were also applied to 
these co morbid factors to observe whether they affect the outcome of the 
study. The p values observed for diabetes mellitus was 0.604 and for 
hypertension was 0.519. Both these values are not statistically significant 
and they did not affect the outcome of the study. 
VENTILATOR AND OUTCOME: 
 In the study group population, 20 patients required ventilator support. 
Out of the 20 patients, 12 patients expired and 8 of them survived. Out of 20 
patients not requiring ventilator support 16 of them survived and 4 patients 
expired. Chi square tests were applied to observe whether the requirement 
of ventilator significantly affect the outcome of the study. The observed p 
value was 0.010, this was statistically significant in affecting the outcome of 
the study. 
APACHE II SCORE AND OUTCOME: 
 APACHE II scores were calculated for all the 40 patients to assess 
whether thyroid function tests could independently predict the outcome of 
78 
 
the patients. Statistical tests were applied to APACHE II scores separately 
to observe whether the scores are statistically significant.  
The observed p value for APACHE II score predicting the mortality 
separately was <0.001**. This result was statistically significant. As 
documented in previous studies, in this study also APACHE II score affects 
the outcome of the patients.  
THYROID PROFILE AND OUTCOME: 
 Thyroid profile was taken from all subjects on day 1 and day 7 as per 
inclusion and exclusion criteria. T3, T4 and TSH values are separately 
subjected to statistical analysis and also they are compared with APACHE II 
score in predicting the outcome. 
 As for day 1, the observed p values for T3 in predicting the outcome 
was 0.087, for T4 was 0.980 and for TSH was 0.085. These values are not 
statistically significant.  The p values, seen on day 7 for T3 in predicting the 
outcome was 0.001, T4 was 0.001 and for TSH was 0.001. All these values 
are statistically significant in predicting the outcome of the patient as an 
independent factor in predicting the outcome of the patient. 
 Again the thyroid profile was compared with APACHE II scores in 
predicting the outcome. On day 1, the observed p values for the correlation 
for T3 was 0.002, T4 was 0.551 and for TSH was 0.216. T3 values on day 1 
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correlated with APACHE II scores in predicting the outcome based on 
statistical analysis. Wang et al in 2012 done a study on relation between 
thyroid function and ICU mortality also showed that low T3 can predict the 
mortality of the patients.  
 Thyroid function tests obtained on day 7 were again compared with 
APACHE II scores in predicting the outcome. Based upon statistical 
analysis the observed p values were 0.001 for T3, 0.010 for T4 and 0.013 
for TSH. All these values are statistically significant. 
 Thyroid profile measured serially in ICU patients can independently 
predict the outcome of the patients. 
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CONCLUSION 
Following results were concluded from the study: 
1) Thyroid profile can be used in predicting the morality in ICU patients. 
2) Serial monitoring of thyroid profile will increase the sensitivity in 
predicting the outcome. 
3) Outcomes assessed by thyroid profile are comparable with that of 
APACHE II scores. 
4)  Thyroid profile can be used as an independent factor in predicting the 
outcome of the patients. 
5)  Thyroid profile can also increase the sensitivity of APACHE II score 
in predicting the outcome. 
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ANNEXURES 
  
 
 
“RELATIONSHIP BETWEEN THYROID FUNCTION AND ICU                         
MORTALITY (SICK EUTHYROID SYNDROME)” 
PROFORMA 
 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
 
 
PAST HISTORY: 
 
THYROID ILLNESS  
HYPERTENSION  
DIABETES MELLITUS  
INTAKE OF ANY OTHER MEDICATIONS  
USAGE OF IODINE CONTRAST AGENTS  
 
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
 
 
 
 
GENERAL EXAMINATION: 
 
GCS  
 
VITAL SIGNS: 
       PR- 
       BP- 
       RR- 
SYSTEMIC  EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 
THYROID EXAMINATION: 
 
INVESTIGATIONS: 
 
COMPLETE  HEMOGRAM 
 
 
 
RFT/ELECTROLYTES 
 
LFT 
 
ECG 
 
APACHE II SCORE 
 
THYROID HORMONE ASSAY  
                DAY 1 
                DAY 7 
OUTCOME 
 
ASSESSMENT : 
S.No Duration 
of stay 
Thyroid 
assay 
day1 
Thyroid 
assay 
day7 
APACHE 
II 
Ventilatory 
support(if) 
Outcome 
3 7 Recovery Death
         
 
 
 

 
 
INFORMATION SHEET 
We are conducting a study on “RELATIONSHIP BETWEEN 
THYROID FUNCTION AND ICU MORTALITY (SICK 
EUTHYROID SYNDROME)” among patients admitted in ICU in Rajiv 
Gandhi Government General Hospital, Chennai and for that your specimen 
may be valuable to us. 
           The purpose of this study is to assess the levels of thyroid hormone in 
acutely ill patients admitted in ICU and the correlation between their levels 
in predicting the mortality in patients who are admitted for more than a 
week. 
We are selecting certain cases and if you are found eligible, we may 
be using your blood samples to do certain tests which in any way do not 
affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
 
Signature of the investigator                                 Signature of the participant 
 
Date:                                                                     Signature of the caregiver 
Place: 
 
 
 
PATIENT CONSENT FORM 
Study Detail : “RELATIONSHIP BETWEEN THYROID 
FUNCTION AND ICU  MORTALITY (SICK 
EUTHYROID SYNDROME)” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction. 

b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
 
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study. 
 
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. 
 
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. 
 
 
 
Signature/thumb impression                                                                       Signature of the investigator 
 
Care giver’s signature                                                                                  Study investigator’s name 
                                                                                                          Dr. M. M. ARUN SHIVA RAMAN  
  
 
 
      ஆராÞÖcoÜpதàக}தÝ 
ஆராய்ச்சி தைலப்ᾗ: 
Avw·ª ]Qaí\œ—«·μ AÒ©vUPœ–mkÇÂ ì{ê¤êÃPÅUS ì{ê¥Ïêμ 
¶−£ íuªê©kâê¯ì©êÔ ©êÍÈ[PíÂ§£ AuÏêμ ¶−£ ·íÂ¹PíÂ§£ 
PshÉ¶íu–ÍÉ¤ Bªê©a]. 
 
ெபயர்: ேததி: 
வயᾐ: உள்ேநாயாளி எண்: 
பால்: ஆராய்ச்சி ேசர்க்ைக எண்: 
 
இந்த ஆராய்ச்சியின் விவரங்கᾦம் அதன் ேநாக்கங்கᾦம் ᾙᾨைமயாக எனக்கு 
ெதளிவாக விளக்கப்பட்டᾐ. எனக்கு விளக்கப்பட்ட விஷயங்கைள நான் ᾗாிந்ᾐ ெகாண்ᾌ 
நான் எனᾐ சம்மதத்ைத ெதாிவிக்கிேறன். 
 
Avw·ª ]Qaí\œ—«·μ AÒ©vUPœ–mkÇÂ ì{ê¤êÃPÅUS ì{ê¥Ïêμ 
¶−£ íuªê©kâê¯ì©êÔ ©êÍÈ[PíÂPshÉ¤ ேமற்ெகாள்ளப்பᾌம் 
பாிேசாதைனகைளப் பற்றிᾜம் ஆராய்ச்சியாளர் கூற ᾙᾨவᾐம் விளங்கப்ெபற்ேறன். 
 
ேமற்ெகாண்ட பாிேசாதைனயின் ேபாᾐ ஏற்படக்கூᾊய பின்விைளᾫகைளᾜம் 
ᾙᾨவᾐம் உணர்ந்ᾐ இந்த பாிேசாதைனக்கு மனமார சம்மதிக்கிேறன். 
 
ைகெயாப்பம்
  
 
“RELATIONSHIP BETWEEN THYROID FUNCTION AND ICU  MORTALITY (SICK EUTHYROID 
SYNDROME)” 
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                   THYROID PROFILE  
 
 
DIAGNOSIS 
 
 
 
 
O
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T
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E
 
                DAY 1              DAY 7 
       T3 T4 TSH T3 T4 TSH   
1 32 F Y Y Y 32 34 3.5 0.84 40 3.8 2.1 SCRUB TYPHUS/ARDS A 
2 38 F N Y Y 38 36 3.6 0.49 41 4 0.55 SIRS-INFECTIVE A 
3 39 M N Y N 33 48 4 0.31 57 4.3 0.32 DIABETIC FOOT/SEPSIS A 
4 58 M Y N Y 42 42 3.8 0.3 35 3.6 0.34 CAD/P EDEMA D 
5 55 M Y Y Y 47 37 3.5 0.68 48 3.9 1.54 ACUTE CVA A 
6 32 M N N N 35 55 4.6 0.88 63 5.2 2.1 HANGING A 
7 48 M Y Y Y 46 32 2.8 0.27 28 2.6 0.24 UROSEPSIS/SEPTIC SHOCK D 
8 28 F N Y N 44 28 3.3 0.26 39 3.9 0.73 T1DM/DKA A 
9 22 M Y N N 43 31 3 1.66 27 3.4 0.9 SNAKE BITE D 
10 43 F N Y N 46 35 3.7 0.21 30 3.3 0.18 EMPHYSEMATOUS PYELONEPHRITIS D 
11 36 M Y Y Y 38 58 4.2 0.53 67 4.6 0.72 OPC POISONING A 
12 42 M Y N Y 37 53 4.1 0.34 45 4 0.32 PONTINE HEMORRHAGE D 
13 45 F N Y N 40 48 4.3 1.5 68 7 0.96 CAD/ACS A 
14 36 F Y Y Y 41 43 4.7 0.36 61 6.9 1 PNEUMONIA A 
15 54 F Y Y Y 45 44 3.9 0.27 37 3.6 0.23 MENINGITIS D 
  
 
16 48 M N Y N 37 53 4.3 0.86 68 5.2 1.56 CAD/ACS/AWMI A 
17 43 M N N N 35 63 4.9 1.23 79 5.7 2.3 SVT A 
18 26 M Y Y N 45 52 4.2 0.29 36 3.8 0.15 SEPSIS/ARDS D 
19 49 F Y N N 38 38 3.1 0.36 51 4.5 0.86 SCORPION STING/P EDEMA A 
20 42 F N Y Y 46 48 4.1 0.86 32 3.9 0.25 CAD/ACS/VT D 
21 60 F N N Y 47 43 4.2 0.18 27 3.8 0.15 SAH D 
22 23 M Y N N 33 72 4.6 0.82 102 6 2.4 OPC POISONING A 
23 32 M Y Y N 42 44 3.9 0.23 33 3.5 0.21 MUCORMYCOSIS-MAXILLARY SINUS D 
24 58 M Y Y Y 35 38 3.6 0.37 51 4.8 0.41 CAD/ACS/NSTEMI A 
25 49 M Y N Y 48 36 3.9 0.34 28 3.3 0.22 CAD/CARDIOGENIC SHOCK D 
26 26 F N Y N 34 62 4.5 0.6 89 8.1 2.1 UROSEPSIS/DKA A 
27 46 M N N Y 37 42 3.6 1.2 91 3.7 2.3 ACUTE CVA A 
28 20 F Y Y N 41 55 4.5 0.41 32 4.1 0.32 SEPSIS/ARDS D 
29 46 M N N Y 35 38 4.2 2.8 62 5.1 3.1 HANGING/PULMONARY EDEMA A 
30 38 F N N Y 26 51 4.1 0.39 73 4.5 0.51 SNAKE BITE/NEUROTOXIC A 
31 43 M Y Y Y 45 43 4.7 0.53 37 4.3 0.46 CAD/DCM/C SHOCK D 
32 32 M N Y N 28 55 3.9 0.36 74 5.4 0.62 OLEANDER SEED POISONING A 
33 65 M Y N Y 44 34 4.3 0.33 33 4.4 0.26 ACUTE CVA/ICH D 
34 29 F N N N 25 54 4.1 0.35 81 5.1 0.56 RAT KILLER PASTE POISONING A 
35 41 M N Y Y 27 61 4.3 1.56 64 5.2 1.77 COMPLICATED MALARIA A 
36 33 F N N N 31 48 3.8 0.92 85 4.6 1.1 COMPLICATED MALARIA A 
37 29 F Y N N 43 54 4.3 1.13 51 4.5 1.15 SNAKE BITE D 
38 25 M N Y N 29 38 3.1 0.61 57 3.5 1.21 T1DM/DKA A 
39 49 F Y N Y 31 55 4.1 0.33 105 4.2 0.35 PNEUMONIA A 
40 56 M N N N 41 33 4.6 0.38 31 3.1 0.16 MENINGITIS D 
  
 
  
 
 
 
 
 
 
